Michael Grey

Michael G.
Grey was the founder of Reneo Pharmaceuticals, Inc., founded in 2014, where the title held was Executive Chairman from 2017 to 2024.
Mr. Grey is the founder of Mirum Pharmaceuticals, Inc., founded in 2018, holding the title of Chairman since 2020.
Current jobs include Chairman at Sorriso Pharmaceuticals, Inc. since 2017; Executive Chairman at Plexium, Inc. since 2021; Executive Chairman at Spruce Biosciences, Inc. since 2022; Vice Chairman at Biothera, Inc.; Executive Chairman at Theolytics Ltd. since 2023; Director at OnKure Therapeutics, Inc. since 2024; and Venture Partner at Pappas Capital LLC since 2010.
Former jobs include President & Chief Executive Officer at SGX Pharmaceuticals, Inc. from 2005 to 2008; President & Chief Executive Officer at Auspex Pharmaceuticals, Inc. in 2009; President & Chief Executive Officer at Lumena Pharmaceuticals, Inc. from 2011 to 2014; President, Chief Executive Officer & Director at Trega Biosciences, Inc. from 1998 to 2001; Non-Executive Chairman at IDM Pharma, Inc. from 1999 to 2009; Executive Chairman at Curzion Pharmaceuticals, Inc. from 2019 to 2020; Executive Chairman at Ziarco Group Ltd. from 2015 to 2017; Director at Amplyx Pharmaceuticals, Inc. from 2020 to 2021; Director at Achillion Pharmaceuticals, Inc. from 2001 to 2010; Lead Independent Director at Horizon Pharma, Inc. from 2013 to 2014; Independent Director at Mirati Therapeutics, Inc. from 2014 to 2021; Lead Independent Director at Horizon Therapeutics Ltd. (Ireland) from 2012 to 2023; Independent Non-Executive Director at BioMarin Pharmaceutical, Inc. from 2014 to 2021; Vice President-Corporate Development at Glaxo Holdings Plc and Glaxo, Inc. from 1974 to 1993; President at Biochem Therapeutic, Inc. from 1994 to 1998; and other director and executive roles at various companies.
Education includes undergraduate studies at The University of Nottingham.